The role of the gastrointestinal microbiome on rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and reactive arthritis: A systematic review

被引:0
|
作者
Ng, Beverly Cheok Kuan [1 ,2 ]
Lassere, Marissa [1 ,2 ]
机构
[1] St George Hosp, Dept Rheumatol, Gray St, Kogarah, NSW 2217, Australia
[2] Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, Australia
关键词
Microbiome; Rheumatoid arthritis; Psoriatic arthritis; Ankylosing spondylitis; ANTI-TNF-ALPHA; GUT-MICROBIOTA; FECAL MICROBIOTA; INTESTINAL MICROBIOME; ASSOCIATION; DYSBIOSIS; REVEALS; PERTURBATIONS; DISEASE;
D O I
10.1016/j.semarthrit.2024.152574
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There is an increasing body of literature observing a state of dysbiosis in the gut microbiome in different autoimmune conditions including inflammatory arthritis. It is unknown whether the microbiome can be a biomarker for prognostication purposes or for stratification of treatment strategies. This review aims to evaluate the existing evidence on the association between the microbiome and inflammatory arthritis, including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) and reactive arthritis (ReA) population groups. Methods: This systematic review was performed based on methods from the Cochrane guidelines and reported based on PRISMA criteria. Studies exploring the microbiome of patients with RA, AS, PsA or ReA compared with controls via 16s rRNA or shotgun sequencing were evaluated. The outcomes of interest include alpha and beta diversity, abundance or depletion of organisms and functional analysis. Literature up to August 2024 was retrieved searching the databases PubMed, Medline, ScienceDirect, Scopus, Web of Science, Cochrane, EMBASE and CINAHL. All references were systematically evaluated by two reviewers. Quality of the studies were evaluated by the Newcastle-Ottawa Scale. Findings: The review yielded 25,794 search results, of which 53 studies were included for the RA group, 34 studies for the AS group, 6 studies for the PsA group and 2 studies for the ReA group. Reduced diversity has been observed in disease groups and in patients with higher disease activity. Interpretation: There are limited longitudinal studies on the role of the microbiome in inflammatory arthritis, in particular PsA. Existing cross-sectional studies suggest altered microbiome in disease states compared with controls. Further studies are required to understand the utility of the microbiome as a biomarker to better understand prognosis and tailor treatments.
引用
收藏
页数:40
相关论文
共 50 条
  • [41] GOLIMUMAB UTILIZATION PATTERNS AND REFILL ADHERENCE IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
    Ellis, L.
    Bolge, S.
    Rice, P.
    VALUE IN HEALTH, 2014, 17 (03) : A49 - A50
  • [42] Golimumab: a new anti-TNF-α agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
    Voulgari, Paraskevi V.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2010, 6 (05) : 721 - 733
  • [43] Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany
    Huscher, D.
    Merkesdal, S.
    Thiele, K.
    Zeidler, H.
    Schneider, M.
    Zink, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (09) : 1175 - 1183
  • [44] PATIENT ELIGIBILITY AND USE OF BIOLOGICS IN RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS IN THE UNITED STATES
    Narayanan, S.
    Baskett, A.
    Lu, Y.
    Hutchings, R.
    VALUE IN HEALTH, 2013, 16 (07) : A572 - A572
  • [45] Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
    Cantini, Fabrizio
    Niccoli, Laura
    Nannini, Carlotta
    Cassara, Emanuele
    Kaloudi, Olga
    Favalli, Ennio Giulio
    Becciolini, Andrea
    Benucci, Maurizio
    Gobbi, Francesca Li
    Guiducci, Serena
    Foti, Rosario
    Mosca, Marta
    Goletti, Delia
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2017, 47 (02) : 183 - 192
  • [46] THE EFFECT OF PREGNANCY ON ANKYLOSING-SPONDYLITIS, PSORIATIC-ARTHRITIS, AND JUVENILE RHEUMATOID-ARTHRITIS
    OSTENSEN, M
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1992, 28 (3-4) : 235 - 237
  • [47] Risk: Benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
    Fleischmann, Roy
    Iqbal, Imran
    DRUGS & AGING, 2007, 24 (03) : 239 - 254
  • [48] Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial
    Ruwaard, J.
    Ami, M. J. L'
    Kneepkens, E. L.
    Krieckaert, C. L. M.
    Nurmohamed, M. T.
    Hooijberg, F.
    van Kuijk, A. W. R.
    van Denderen, J. C.
    Burgemeister, L.
    Rispens, T.
    Boers, M.
    Wolbink, G. J.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 (02) : 129 - 136
  • [49] Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience
    Moura, Cristiano S.
    Choquette, Denis
    Coupal, Louis
    Bessette, Louis
    Bernatsky, Sasha
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [50] Risk: Benefit Profile of Etanercept in Elderly Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis
    Roy Fleischmann
    Imran Iqbal
    Drugs & Aging, 2007, 24 : 239 - 254